IN8bio (NASDAQ:INAB – Free Report) had its target price reduced by HC Wainwright from $12.50 to $8.00 in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.
IN8bio Price Performance
NASDAQ:INAB traded up $0.00 during trading hours on Wednesday, reaching $0.32. The stock had a trading volume of 47,917 shares, compared to its average volume of 546,124. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.66 and a current ratio of 2.66. The stock has a market capitalization of $14.82 million, a PE ratio of -0.42 and a beta of -0.07. IN8bio has a 52 week low of $0.22 and a 52 week high of $2.48. The company has a 50 day moving average price of $0.30 and a two-hundred day moving average price of $0.68.
Institutional Trading of IN8bio
A hedge fund recently raised its stake in IN8bio stock. Sigma Planning Corp boosted its stake in shares of IN8bio, Inc. (NASDAQ:INAB – Free Report) by 42.0% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 851,280 shares of the company’s stock after buying an additional 251,600 shares during the period. Sigma Planning Corp owned approximately 1.82% of IN8bio worth $230,000 at the end of the most recent quarter. 92.05% of the stock is currently owned by institutional investors and hedge funds.
IN8bio Company Profile
IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.
Further Reading
- Five stocks we like better than IN8bio
- What is the Dow Jones Industrial Average (DJIA)?
- Top 3 R&D-Driven Stocks Showing Strong Profit and Momentum
- Do ETFs Pay Dividends? What You Need to Know
- Shopify Stock Rally Continues: Why the Growth Story Isn’t Over
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Tariff Troubles: 3 Stocks Planning Higher Prices
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.
